Reported November 14, 2026. China’s 2026 national basic medical insurance catalogue includes relmacabtagene autoleucel injection, marketed as Benoda by JW Therapeutics. According to the original report, it is the first—and, at the time of publication, only—CAR-T therapy included in the catalogue.
CAR-T treatments are made individually for patients, contributing to high production costs. Their prices in China have commonly been around 1 million yuan. JW Therapeutics chairman and CEO Tian Feng told reporters that negotiations with insurance officials involved repeated discussions over a price that would reduce patients’ costs while remaining viable for the company.
The negotiated price was not disclosed. An unnamed industry source cited in the report estimated that the price could fall below 300,000 yuan and that patients might pay less than 100,000 yuan after reimbursement. Those figures are estimates, not confirmed prices or out-of-pocket costs.
Tian attributed the company’s room to lower its price partly to greater control over its lentiviral-vector production technology, which he said reduced reliance on costly overseas materials. He said demand after insurance coverage takes effect remains difficult to predict, but that the company has production capacity in reserve at its Suzhou facility.
The therapy had entered China’s first commercial-insurance catalogue for innovative drugs in 2025. Tian said commercial insurance had supported about one-third of the more than 200 patients the company treated annually, without yet producing a large direct increase in use.
